Trial Details

Not Recruiting
Basic Information
Clinical ID c2144
Identifier CTIS2023-507425-42-00
Trial Title A Prospective, Randomized, Placebo-controlled Clinical Trial of oral vancomycin in adults and young adults (15-17 years old) affected by Primary Sclerosing Cholangitis with or without Inflammatory Bowel Disease - VanC-IT
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Primary Sclerosing Cholangitis MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805;Therapeutic area: Diseases [C] - Digestive System Diseases [C06];MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805
Interventions Product Name: , Product Code:SCP32734155, Pharmaceutical Form: , Other descriptive name: , Strength: , Product Name: Placebo capsules contain the only excipient present in the formulation, Polyethylene glycol 6000; the active ingredient is substituted by the same excipient to obtain the intended filling weight. The pharmaceutical form is white/white 00 hard gelatin capsules for oral administration., Product Code:N/A, Pharmaceutical Form: N/A, Other descriptive name: N/A , Strength: , Pharmaceutical form of the placebo: N/A
Participant Information
Sponsor University Of Milano Bicocca
City -
Country/Region Italy
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, CHILD, INFANT, OLDER_ADULT, TEENAGER
Study Design
Study Type Interventional clinical trial of medicinal product
Phase PHASE2
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -